Moderna: Jefferies raises target price

(CercleFinance.com) - Jefferies maintains its "hold" rating on Moderna shares, while increasing its target price for them from 170 dollars to 250 dollars, ahead of the biotech company's Q2 results.


The broker expects Moderna to raise its 2021 guidance from 19 to 21 billion dollars, in addition to an upbeat speech, although notes that its new target price suggests a 100 billion dollar valuation, despite uncertainties.


Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.